BioAegis

BioAegis Therapeutics is a clinical stage biotechnology company commercializing ground breaking medical discoveries in inflammation and infection.

[BioAegis @BioAegis]

BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS) https://t.co/dmTInGAzH2

[BioAegis @BioAegis]

Clinical Trial Update --Over 23 sites in 7 countries are live. First patients have been enrolled in both Europe and US. 600-person global phase 2 #clinicaltrial of recombinant human plasma #gelsolin (rhu-pGSN) for moderate to severe Acute Respiratory Distress Syndrome (#ARDS)

[BioAegis @BioAegis]

https://t.co/QUk3QO4Kf9

[BioAegis @BioAegis]

https://t.co/QUk3QO4Kf9

[BioAegis @BioAegis]

Major milestone for BioAegis. https://t.co/QUk3QO4Kf9

[BioAegis @BioAegis]

Major milestone for BioAegis. https://t.co/QUk3QO4Kf9

[BioAegis @BioAegis]

https://t.co/QUk3QO4Kf9

[BioAegis @BioAegis]

register here: https://t.co/GuXVp7tOMb

[BioAegis @BioAegis]

#Rarediseases aren't that rare and there is a large unmet need for treatments. Join us for a free webinar tomorrow, May 23 at 2PM ET. #autoinflammatory disease #immunesystem #cytokinestorm https://t.co/GuXVp7tOMb

[BioAegis @BioAegis]

Join us for a webinar on the rapidly growing field of #autoinflammatory and #hyperinflammatory diseases - what we know and need to know moving forward. #inflammation #RareDisease #innateimmunesystem #inflammasomes #cytokinestorm https://t.co/BdBrcfA8tO

[BioAegis @BioAegis]

Join us for a webinar on the rapidly growing field of #autoinflammatory and #hyperinflammatory diseases - what we know and need to know moving forward. #inflammation #RareDisease #innateimmunesystem #inflammasomes #cytokinestorm https://t.co/BdBrcfA8tO

[BioAegis @BioAegis]

https://t.co/hCvSs9j6PI
Two independent studies explored #gelsolin's role in type 2 #diabietes. #Bioaegis' human recombinant plasma gelsolin is a host-directed approach to treating #inflammatorydiseases.

[BioAegis @BioAegis]

Exciting news for us and our product, recombinant human plasma gelsolin. 2 studies explored #gelsolin’s role in type 2 #inflammatorydisease

[BioAegis @BioAegis]

https://t.co/hCvSs9j6PI

[BioAegis @BioAegis]

There are NO current therapies other than supportive care for #ARDS. We just received #FDA clearance to proceed with our #IND for #gelsolin 'inflammation regulatory protein' treatment. #lunginjury #inflammation #savinglives
https://t.co/3l2KXR0H96

[BioAegis @BioAegis]

We received #FDA clearance to proceed with our Investigational New Drug (#IND) for #gelsolin, for the treatment of acute respiratory distress syndrome (#ARDS).https://t.co/3l2KXR0H96

[BioAegis @BioAegis]

Received #FDA approval for our Investigational New Drug (#IND) application for our human protein, #gelsolin, for the treatment of acute respiratory distress syndrome. (#ARDS).https://t.co/3l2KXR0H96

[BioAegis @BioAegis]

https://t.co/3l2KXR0H96

[BioAegis @BioAegis]

https://t.co/3Sysjsgwyc